Novo Nordisk Takes On Sanofi Over Insulin Pens
Wasting no time in enforcing the rights to its invention, Novo Nordisk filed the suit on July 10, the same day that the U.S. Patent and Trademark Office issued the patent entitled “injection device.”
Novo Nordisk claims that Sanofi-Aventis' SoloStar, a prefilled disposable insulin pen, violates the patent. The Danish company is seeking an...
To view the full article, register now.